Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome

Figures & data

Table 1. Demographic characteristics of the two groups in this study

Parameters	NS (n = 24)	Control (n = 24)	P
Age (years)	37 ± 9	32 ± 8	ns
Sex (female/male)	12/12	11/13	ns
Body mass index (kg/m^2)	23.5 ± 1.3	21.4 ± 1.1	ns
Proteinuria (mg/24 hours)	1215 ± 742	120 ± 61	P < 0.05
Systolic blood pressure (mmHg)	120 ± 12	120 ± 10	ns
Diastolic blood pressure (mmHg)	80 ± 8	82 ± 10	ns
GFR (ml/minute)	126.9 ± 14.1	122.5 ± 12.8	ns
Albumin (g/l)	38.2 ± 9.1	45.1 ± 4.2	P < 0.05
TG (mmol/l)	2.46 ± 0.90	1.22 ± 0.34	P < 0.05
TC (mmol/l)	6.33 ± 1.71	4.57 ± 0.57	P < 0.05
HDL-C (mmol/l)	1.05 ± 0.24	1.19 ± 0.29	P < 0.05
LDL-C (mmol/l)	4.14 ± 1.47	2.79 ± 0.64	P < 0.05

GFR, glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; NS, nephrotic syndrome; ns, non-significant; TG, triglyceride; TC, total cholesterol.

Values are mean ± SD.

Figure 1. Serum MPO activity in the nephrotic syndrome patients and control subjects

Figure 2. Serum malondialdehyde levels in the nephrotic syndrome patients and control subjects

Figure 3. Serum catalase activity in the nephrotic syndrome patients and control subjects

Table 2. MPO activity, catalase activity and oxidative stress in NS patients and controls

Parameters	NS (n = 24)	Controls (n = 24)	P
Malondialdehyde (nmol/ml)	10.84 ± 1.48	5.32 ± 1.51	P < 0.001
MPO activity (U/l)	59.21 ± 14.76	42.61 ± 20.11	P < 0.002
Catalase (U/l)	13.49 ± 3.67	71.84 ± 30.02	P < 0.001

NS, nephrotic syndrome.

Values are mean ± SD.